HRP950149A2 - Intranasal antimigrene composition - Google Patents

Intranasal antimigrene composition Download PDF

Info

Publication number: HRP950149A2
Authority: HR; Croatia
Prior art keywords: chitosan; composition; composition according; acid; pharmaceutically acceptable
Prior art date: 1994-04-13

Application number

HR94200998.6A

Other languages

English (en)

Croatian (hr)

Inventor

Marck Karel Jozef Francois

Roger Carolus August Embrechts

Lisbeth Illum

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-04-13

Filing date

1995-03-27

Publication date

1997-06-30

1995-03-27 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

1997-06-30 Publication of HRP950149A2 publication Critical patent/HRP950149A2/hr

Links

239000000203 mixture Substances 0.000 title claims abstract description 61
229920001661 Chitosan Polymers 0.000 claims abstract description 37
150000001875 compounds Chemical class 0.000 claims abstract description 15
239000003814 drug Substances 0.000 claims abstract description 11
239000007922 nasal spray Substances 0.000 claims abstract description 5
229940097496 nasal spray Drugs 0.000 claims abstract description 5
150000003839 salts Chemical class 0.000 claims description 20
239000002253 acid Substances 0.000 claims description 17
239000004480 active ingredient Substances 0.000 claims description 15
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 7
230000006196 deacetylation Effects 0.000 claims description 6
238000003381 deacetylation reaction Methods 0.000 claims description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
229930195712 glutamate Natural products 0.000 claims description 5
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
238000000034 method Methods 0.000 claims description 3
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
GDNITZYKOOTAFK-QCUBGVIVSA-N n-[[(2r)-3,4-dihydro-2h-chromen-2-yl]methyl]-n'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine;dihydrochloride Chemical compound Cl.Cl.C([C@@H]1OC2=CC=CC=C2CC1)NCCCNC1=NCCCN1 GDNITZYKOOTAFK-QCUBGVIVSA-N 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 1
229910002651 NO3 Inorganic materials 0.000 claims 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 claims 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
230000002460 anti-migrenic effect Effects 0.000 abstract description 6
238000004519 manufacturing process Methods 0.000 abstract description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
239000000243 solution Substances 0.000 description 12
208000019695 Migraine disease Diseases 0.000 description 8
206010027599 migraine Diseases 0.000 description 8
229940079593 drug Drugs 0.000 description 7
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
-1 3,4-dihydro-2H-1-benzopyran-2-yl Chemical group 0.000 description 5
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 5
239000007921 spray Substances 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
235000011054 acetic acid Nutrition 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000005507 spraying Methods 0.000 description 4
239000005526 vasoconstrictor agent Substances 0.000 description 4
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 3
238000010579 first pass effect Methods 0.000 description 3
230000002440 hepatic effect Effects 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
210000003928 nasal cavity Anatomy 0.000 description 3
210000002381 plasma Anatomy 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 2
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
229920002101 Chitin Polymers 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
230000002411 adverse Effects 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
QVSXOXCYXPQXMF-UHFFFAOYSA-N alniditan Chemical compound C1CC2=CC=CC=C2OC1CNCCCNC1=NCCCN1 QVSXOXCYXPQXMF-UHFFFAOYSA-N 0.000 description 2
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229940124433 antimigraine drug Drugs 0.000 description 2
229960000686 benzalkonium chloride Drugs 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
230000007794 irritation Effects 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
150000002688 maleic acid derivatives Chemical class 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
229910017604 nitric acid Inorganic materials 0.000 description 2
QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
239000003223 protective agent Substances 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
BIDXGEXQRVWXMY-UHFFFAOYSA-N 1-azaniumylpropylazanium;dichloride Chemical compound Cl.Cl.CCC(N)N BIDXGEXQRVWXMY-UHFFFAOYSA-N 0.000 description 1
WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
ZPDQFUYPBVXUKS-YADHBBJMSA-N 1-stearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OC[C@H](N)C(O)=O ZPDQFUYPBVXUKS-YADHBBJMSA-N 0.000 description 1
CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
SBQRYMGLABMVAQ-UHFFFAOYSA-N 2-(1,2-dihydroxypropyl)propanedioic acid Chemical compound CC(O)C(O)C(C(O)=O)C(O)=O SBQRYMGLABMVAQ-UHFFFAOYSA-N 0.000 description 1
GWNIBSQWAZQIEJ-UHFFFAOYSA-N 2-(1-hydroxypropyl)propanedioic acid Chemical compound CCC(O)C(C(O)=O)C(O)=O GWNIBSQWAZQIEJ-UHFFFAOYSA-N 0.000 description 1
IDRUFHLMTBZQBT-IHWYPQMZSA-N 2-[(Z)-prop-1-enyl]propanedioic acid Chemical compound C\C=C/C(C(O)=O)C(O)=O IDRUFHLMTBZQBT-IHWYPQMZSA-N 0.000 description 1
IDRUFHLMTBZQBT-NSCUHMNNSA-N 2-[(e)-prop-1-enyl]propanedioic acid Chemical compound C\C=C\C(C(O)=O)C(O)=O IDRUFHLMTBZQBT-NSCUHMNNSA-N 0.000 description 1
LODHFNUFVRVKTH-ZHACJKMWSA-N 2-hydroxy-n'-[(e)-3-phenylprop-2-enoyl]benzohydrazide Chemical compound OC1=CC=CC=C1C(=O)NNC(=O)\C=C\C1=CC=CC=C1 LODHFNUFVRVKTH-ZHACJKMWSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
WRFYIYOXJWKONR-UHFFFAOYSA-N 4-bromo-2-methoxyaniline Chemical compound COC1=CC(Br)=CC=C1N WRFYIYOXJWKONR-UHFFFAOYSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
241000238557 Decapoda Species 0.000 description 1
206010013911 Dysgeusia Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
206010021518 Impaired gastric emptying Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
206010052437 Nasal discomfort Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
206010047141 Vasodilatation Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 description 1
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
159000000021 acetate salts Chemical group 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000001361 adipic acid Substances 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000002585 base Substances 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
JBIROUFYLSSYDX-UHFFFAOYSA-M benzododecinium chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 JBIROUFYLSSYDX-UHFFFAOYSA-M 0.000 description 1
229960004074 benzododecinium chloride Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
IBNQLYMPUGQNLN-UHFFFAOYSA-M benzyl-[2-(4-dodecanoylphenoxy)ethyl]-dimethylazanium;chloride Chemical compound [Cl-].C1=CC(C(=O)CCCCCCCCCCC)=CC=C1OCC[N+](C)(C)CC1=CC=CC=C1 IBNQLYMPUGQNLN-UHFFFAOYSA-M 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
210000001627 cerebral artery Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
229960002798 cetrimide Drugs 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
230000029142 excretion Effects 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
150000004675 formic acid derivatives Chemical class 0.000 description 1
239000012458 free base Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
208000001288 gastroparesis Diseases 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000002306 glutamic acid derivatives Chemical class 0.000 description 1
235000011167 hydrochloric acid Nutrition 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229950007325 lauralkonium chloride Drugs 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
150000002690 malonic acid derivatives Chemical class 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
GDNITZYKOOTAFK-UHFFFAOYSA-N n-(3,4-dihydro-2h-chromen-2-ylmethyl)-n'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine;dihydrochloride Chemical compound Cl.Cl.C1CC2=CC=CC=C2OC1CNCCCNC1=NCCCN1 GDNITZYKOOTAFK-UHFFFAOYSA-N 0.000 description 1
229950006780 n-acetylglucosamine Drugs 0.000 description 1
230000008693 nausea Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
229940067107 phenylethyl alcohol Drugs 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000004302 potassium sorbate Substances 0.000 description 1
235000010241 potassium sorbate Nutrition 0.000 description 1
229940069338 potassium sorbate Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
229940070891 pyridium Drugs 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
238000005070 sampling Methods 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000002602 strong irritant Substances 0.000 description 1
150000003890 succinate salts Chemical class 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
230000008673 vomiting Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Otolaryngology (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HR94200998.6A 1994-04-13 1995-03-27 Intranasal antimigrene composition HRP950149A2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP94200998		1994-04-13

Publications (1)

Publication Number	Publication Date
HRP950149A2 true HRP950149A2 (en)	1997-06-30

Family

ID=8216793

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR94200998.6A HRP950149A2 (en)	1994-04-13	1995-03-27	Intranasal antimigrene composition

Country Status (23)

Country	Link
EP (1)	EP0755253B1 (fr)
JP (1)	JP2921988B2 (fr)
KR (1)	KR100219952B1 (fr)
CN (1)	CN1146151A (fr)
AT (1)	ATE194915T1 (fr)
AU (1)	AU684360B2 (fr)
BG (1)	BG62197B1 (fr)
BR (1)	BR9507369A (fr)
CA (1)	CA2184822C (fr)
CZ (1)	CZ286610B6 (fr)
DE (1)	DE69518149T2 (fr)
FI (1)	FI118295B (fr)
HR (1)	HRP950149A2 (fr)
HU (1)	HU219495B (fr)
IL (1)	IL113341A (fr)
NO (1)	NO310276B1 (fr)
NZ (1)	NZ284454A (fr)
PL (1)	PL179761B1 (fr)
RO (1)	RO115414B1 (fr)
SI (1)	SI9500121A (fr)
SK (1)	SK129896A3 (fr)
WO (1)	WO1995028158A1 (fr)
ZA (1)	ZA953038B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9403905D0 (sv) *	1994-11-14	1994-11-14	Astra Ab	New formulations
KR970032844A (ko) *	1995-12-29	1997-07-22	김준웅	지속성 경비투여제제
UA72189C2 (uk) *	1997-11-17	2005-02-15	Янссен Фармацевтика Н.В.	Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
GB2378383A (en) *	2001-06-06	2003-02-12	Gursharan Moonga	Nasal delivery of pharmaceutical compositions in powder form
GB0328186D0 (en) *	2003-12-05	2004-01-07	West Pharm Serv Drug Res Ltd	Intranasal compositions
US7968122B2 (en)	2003-12-10	2011-06-28	Adventrx Pharmaceuticals, Inc.	Anti-viral pharmaceutical compositions
NL2022788B1 (en) *	2019-03-22	2020-09-28	No Ceuticals B V	Chitosan nitrate for use as a nitric oxide donor (NO donor)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4946870A (en) *	1986-06-06	1990-08-07	Union Carbide Chemicals And Plastics Company Inc.	Delivery systems for pharmaceutical or therapeutic actives
GB8904370D0 (en) *	1989-02-25	1989-04-12	Cosmas Damian Ltd	Liquid delivery compositions
SI9300097B (en) *	1992-02-27	2001-12-31	Janssen Pharmaceutica Nv	(benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
JPH0656675A (ja) *	1992-08-07	1994-03-01	Nippon Soda Co Ltd	家畜の乳房炎予防剤

1995
- 1995-03-27 HR HR94200998.6A patent/HRP950149A2/hr not_active Application Discontinuation
- 1995-04-10 PL PL95316756A patent/PL179761B1/pl unknown
- 1995-04-10 AT AT95916618T patent/ATE194915T1/de active
- 1995-04-10 BR BR9507369A patent/BR9507369A/pt not_active Application Discontinuation
- 1995-04-10 RO RO96-01974A patent/RO115414B1/ro unknown
- 1995-04-10 NZ NZ284454A patent/NZ284454A/en not_active IP Right Cessation
- 1995-04-10 WO PCT/EP1995/001302 patent/WO1995028158A1/fr not_active Ceased
- 1995-04-10 CN CN95192535A patent/CN1146151A/zh active Pending
- 1995-04-10 HU HU9602806A patent/HU219495B/hu unknown
- 1995-04-10 EP EP95916618A patent/EP0755253B1/fr not_active Expired - Lifetime
- 1995-04-10 DE DE69518149T patent/DE69518149T2/de not_active Expired - Lifetime
- 1995-04-10 KR KR1019960705599A patent/KR100219952B1/ko not_active Expired - Lifetime
- 1995-04-10 SK SK1298-96A patent/SK129896A3/sk unknown
- 1995-04-10 AU AU23054/95A patent/AU684360B2/en not_active Expired
- 1995-04-10 CZ CZ19962920A patent/CZ286610B6/cs not_active IP Right Cessation
- 1995-04-10 JP JP7526682A patent/JP2921988B2/ja not_active Expired - Lifetime
- 1995-04-10 CA CA002184822A patent/CA2184822C/fr not_active Expired - Lifetime
- 1995-04-12 IL IL11334195A patent/IL113341A/xx not_active IP Right Cessation
- 1995-04-12 SI SI9500121A patent/SI9500121A/sl unknown
- 1995-04-12 ZA ZA953038A patent/ZA953038B/xx unknown
1996
- 1996-10-08 BG BG100889A patent/BG62197B1/bg unknown
- 1996-10-11 NO NO19964333A patent/NO310276B1/no not_active IP Right Cessation
- 1996-10-11 FI FI964095A patent/FI118295B/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
NZ284454A (en)	1997-12-19
NO310276B1 (no)	2001-06-18
BG100889A (en)	1997-07-31
PL179761B1 (pl)	2000-10-31
BR9507369A (pt)	1997-09-23
KR100219952B1 (ko)	1999-09-01
IL113341A (en)	2000-08-31
CN1146151A (zh)	1997-03-26
FI964095L (fi)	1996-10-11
DE69518149D1 (de)	2000-08-31
EP0755253A1 (fr)	1997-01-29
WO1995028158A1 (fr)	1995-10-26
AU2305495A (en)	1995-11-10
IL113341A0 (en)	1995-07-31
BG62197B1 (bg)	1999-05-31
HU9602806D0 (en)	1996-11-28
NO964333L (no)	1996-10-11
CA2184822A1 (fr)	1995-10-26
JP2921988B2 (ja)	1999-07-19
RO115414B1 (ro)	2000-02-28
AU684360B2 (en)	1997-12-11
FI118295B (fi)	2007-09-28
SK129896A3 (en)	1997-05-07
NO964333D0 (no)	1996-10-11
HU219495B (hu)	2001-04-28
SI9500121A (en)	1995-10-31
PL316756A1 (en)	1997-02-03
ATE194915T1 (de)	2000-08-15
CZ286610B6 (cs)	2000-05-17
FI964095A0 (fi)	1996-10-11
ZA953038B (en)	1996-10-14
HUT75939A (en)	1997-05-28
JPH09505606A (ja)	1997-06-03
CZ292096A3 (en)	1997-02-12
DE69518149T2 (de)	2001-03-22
EP0755253B1 (fr)	2000-07-26
CA2184822C (fr)	2000-12-19

Legal Events

Date	Code	Title
1997-06-30	A1OB	Publication of a patent application
1997-08-13	AIPI	Request for the grant of a patent on the basis of a substantive examination of a patent application
2001-05-18	ODBC	Application rejected

Publication	Publication Date	Title
JP3278192B2 (ja)	2002-04-30	徐放性液剤
EP0524587B1 (fr)	1995-11-29	Compositions thérapeutiques pour l'administration intranasale contenant ketorolac R
RU1837869C (ru)	1993-08-30	Способ получени дисперсии полипептидов дл интраназольного применени
JP3350061B2 (ja)	2002-11-25	エレトリプタンヘミスルフェートおよびカフェインを含有する医薬組成物
CN101511337B (zh)	2013-12-11	吸收增强的经粘膜递送装置
CA2374877C (fr)	2004-04-13	Formulations pharmaceutiques et procedes comprenant de la morphine s'administrant par voie intra-nasale
JP2002523453A (ja)	2002-07-30	鼻膜へ亜鉛送達するための方法及び組成物
JP2003501468A (ja)	2003-01-14	アポモルヒネの経鼻送達
US4876283A (en)	1989-10-24	Antisnoring agent
WO2013024373A1 (fr)	2013-02-21	Composition pharmaceutique comprenant du céfuroxime
US6387917B1 (en)	2002-05-14	Salts of opioid analgesics, particularly morphine, and methods of using same
BRPI0311511B1 (pt)	2018-07-10	"preparações farmacêuticas líquidas, e sua aplicação".
US6054462A (en)	2000-04-25	Intranasal antimigraine compositions
HUP0203339A2 (hu)	2003-02-28	Nyálkahártyára juttatandó, ciclesonidot tartalmazó gyógyászati készítmény
EP0755253B1 (fr)	2000-07-26	Composition intranasale antimigraineuse
EP1237538A2 (fr)	2002-09-11	Composition pharmaceutique amelioree pour traiter la dyserection masculine
MXPA06009094A (es)	2007-02-02	Formulaciones de liberacion controlada.
JPH01160916A (ja)	1989-06-23	ドーパミン経鼻投与製剤
JPH0480008B2 (fr)	1992-12-17
JP2002536401A (ja)	2002-10-29	メタミゾール含有起泡性医薬組成物
JPH05170663A (ja)	1993-07-09	カルシトニン点鼻用医薬組成物
WO2024180339A1 (fr)	2024-09-06	Formulation liquide comprenant du trilostane
EP0323762A1 (fr)	1989-07-12	Nouvelles compositions anti-tussives et leur procédé d'obtention
JPH10259124A (ja)	1998-09-29	咽頭疾患用組成物
JPWO1998046269A1 (ja)	2000-10-03	経粘膜投与製剤